jcm-logo

Journal Browser

Journal Browser

Novel Diagnostic and Therapeutic Approaches to Urologic Oncology

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 April 2026 | Viewed by 732

Special Issue Editors


E-Mail Website
Guest Editor
1. “St. John” Emergency Clinical Hospital, 042122 Bucharest, Romania
2. Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: endourology; basic research on the diagnosis of benign prostatic hyperplasia and prostate cancer; urolithiasis; uro-oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Urology, “St. John” Emergency Clinical Hospital, 042122 Bucharest, Romania
2. Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: endourology; benign prostatic hyperplasia; urolithiasis; uro-oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Urology and Renal Transplantation, Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
Interests: uro-oncology; robotic urology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Urologic oncology is one of the most dynamic fields of medicine, with research focused on various fronts, including improvements in developing new tumor markers with increasing roles in early diagnosis and tumor staging. New imaging protocols for prostate cancer and bladder cancer, along with novel chemotherapy regimens and the advancement of targeted and personalized therapies such as immunotherapy and genetic approaches, have led to unprecedented public interest in this field.

In this Special Issue, we hope to present the latest discoveries in this field, and welcome submissions that discuss diagnostic or therapeutic strategies in early and advanced urologic oncology, focusing on prostate cancer, bladder cancer, upper urinary tract tumors, renal tumors, testicular or penile cancer, and urethral cancer.

You may choose our Joint Special Issue in Journal of Personalized Medicine.

Dr. Cosmin-Victor Ene
Prof. Dr. Bogdan Florin Geavlete
Dr. Cristian I. Surcel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnosis
  • therapy
  • up-to-date
  • uro-oncologic pathology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 514 KB  
Article
Prognostic Value of the SUVmax–IPI Composite Score on Overall Survival in Metastatic Prostate Cancer
by Emine Türkmen, Atike Pınar Erdoğan, Mustafa Şahbazlar, Gözde Mütevelizade and Ferhat Ekinci
J. Clin. Med. 2026, 15(7), 2655; https://doi.org/10.3390/jcm15072655 - 31 Mar 2026
Viewed by 369
Abstract
Objective: This study aimed to evaluate the prognostic value of the SUVmax–IPI composite score, generated by integrating the maximum standardized uptake value (SUVmax) derived from metastatic 68Ga-PSMA PET/CT imaging with the inflammatory prognostic index (IPI), in predicting overall survival in patients with [...] Read more.
Objective: This study aimed to evaluate the prognostic value of the SUVmax–IPI composite score, generated by integrating the maximum standardized uptake value (SUVmax) derived from metastatic 68Ga-PSMA PET/CT imaging with the inflammatory prognostic index (IPI), in predicting overall survival in patients with metastatic prostate cancer. Materials and Methods: This retrospective, single-center cohort study included 146 patients diagnosed with metastatic prostate adenocarcinoma between 2009 and 2025. Among them, 125 patients with available PET/CT imaging were included in the SUVmax–IPI analysis. The composite score was calculated by multiplying the metastatic SUVmax value by the IPI. The optimal cut-off value was determined using receiver operating characteristic curve analysis. Overall survival was evaluated using the Kaplan–Meier method and compared using the log-rank test. Independent prognostic factors were identified using multivariable Cox proportional hazards regression analysis with a forward (stepwise) selection approach. Results: Using the predefined cut-off value (82), the median overall survival was 125 months in patients with SUVmax–IPI ≤ 82 and 19 months in those with SUVmax–IPI > 82 (log-rank p = 0.001). In the forward multivariable Cox regression model, SUVmax–IPI > 82 remained independently associated with worse overall survival after adjustment for ALP, AST, PSA nadir, and androgen deprivation modality (hazard ratio [HR]: 7.92; 95% confidence interval [CI]: 2.97–21.10; p < 0.001). Conclusions: The SUVmax–IPI composite score, integrating PSMA PET/CT-derived metabolic tumor activity with systemic inflammatory burden, is independently associated with overall survival in metastatic prostate cancer. These findings suggest that combining metabolic and inflammatory parameters may enhance prognostic stratification beyond conventional clinical and biochemical markers. Full article
(This article belongs to the Special Issue Novel Diagnostic and Therapeutic Approaches to Urologic Oncology)
Show Figures

Graphical abstract

Back to TopTop